Innovation Potential

Our project has a strong innovation potential, enabling research findings to be transferred from the bed to bench and back again, thanks to the different partners involved in the UM Cure 2020 consortium. Indeed, the four major referral hospitals for UM patients across Europe will team up with three other research institutions and two innovative SMEs in diagnostics and cancer therapeutics.  

PEP-Therapy

PEP-Therapy ia a biotech company developing proprietary Cell Penetrating & Interfering Peptides (CP&IP) as targeted therapies for cancer treatment. CP&IP combine an optimised cell-penetrating peptide as a “shuttle” for delivery of active molecules into the cell (without apparent toxicity and with optimised in vivo stability), with active peptides targeting relevant protein-protein interactions. CP&IP specifically block key cellular mechanisms of diseases without any effect on functions of other proteins or pathways, thereby limiting potential side effects. UM Cure 2020 will be an opportunity for PT to move forward the development of its promising CP&IP targeting the Hippo pathway up to pre-GLP toxicity studies, to be ready to initiate clinical trials if successful.

PamGene

PamGene will be instrumental in the clinical translation of our results. Using its commercial expertise in the emerging markets of precision medicine and by providing its innovative and proprietary technology platform for companion diagnostics, PG will significantly strengthen our proposal. The UM PamChip® peptide microarray, specifically developed for the project, will later represent a commercial opportunity for this SME. Importantly, the subsequent application of the UM PamChip® in clinical trials will increase the chances of successful trial through improved patient stratification, and will ultimately advance clinical practice of UM treatment and management. No competing tool based on a similar proteomic technology currently exists for UM. 

Follow us